Criteria for Discontinuing Treatment With an Amyloid-Targeting Therapy

Panelists discuss how treatment continuation decisions for amyloid-targeting therapies involve comprehensive assessment of multiple factors including cognitive and functional changes measured through standardized tools, occurrence and severity of adverse events, treatment adherence capabilities, impact on patient/caregiver quality of life, disease progression rate, emerging safety signals, and ongoing dialogue about evolving treatment goals and expectations.

EP: 1.Strategies for Enhancing Early Diagnosis and Implementation of Disease-Modifying Therapies in Alzheimer Disease

EP: 2.Advancing Early Alzheimer Diagnosis: Best Practices for Timely Screening and Detection

EP: 3.Care Pathways for Nonspecialist Providers When Evaluating Patients With Potential Mild Cognitive Impairment

EP: 4.Empowering Nonspecialist Providers and Addressing Gaps in Dementia Care: How Tools and Biomarkers Can Help

EP: 5.Factors to Evaluate When Selecting a Combination of Screening Assessments and Tests for Detecting Alzheimer Disease

EP: 6.From Time Constraints to Reimbursement: Addressing Key Hurdles in Cognitive Screening for Alzheimer Disease

EP: 7.Expanding Access to Alzheimer Disease Care: Leveraging Referral Networks and Telemedicine for Patients in Underserved Areas

EP: 8.Amyloid-Targeting Therapies in Alzheimer Disease: Mechanisms of Action, Efficacy, and Safety Considerations

EP: 9.Real-World Implications of Changes in CDR-SB Score in Patients Receiving Amyloid-Targeting Therapy

EP: 10.Patient Selection for Amyloid-Targeting Therapies: Key Characteristics and Considerations

EP: 11.Understanding the Hesitancy to Prescribe Amyloid-Targeting Therapies for Patients With Alzheimer Disease

EP: 12.Navigating the Risk-Benefit Conversation: Discussing Amyloid-Targeting Therapies With Patients and Caregivers

Now Viewing

EP: 13.Criteria for Discontinuing Treatment With an Amyloid-Targeting Therapy

EP: 14.Strategies for Clinicians When Developing Protocols for Managing ARIA

EP: 15.Key Barriers in Managing Patients With Mild Cognitive Impairment Using Amyloid-Targeting Therapies

EP: 16.Access to Diagnostic Tests and Coverage for Amyloid-Targeting Therapies: Payer Considerations

EP: 17.Addressing Concerns About the Financial Impact of Amyloid-Targeting Therapies

EP: 18.Final Thoughts Alzheimer Disease Care

Video content above is prompted by the following:

• How do you decide whether to continue or discontinue treatment with an amyloid-targeting therapy?

Related Videos

Related Content

Advertisement

July 25th 2025

Genetic Study Finds Hypothyroidism May Increase PAH Risk

Maggie L. Shaw

A nascent hypothesis regarding pulmonary arterial hypertension (PAH) is that there is a link between thyroid dysfunction and PAH risk; much remains to be investigated to prove causality.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 24th 2025

High Burdens of Drug Resistance Found in Children With HIV

Julia Bonavitacola

Mother-to-child transmission often led to pretreatment drug resistance and acquired drug resistance in children living with HIV.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 23rd 2025

Immune Cell Phenotypes Linked With Hypothyroidism, IPF

Jared Kaltwasser

Thirty-six immune cell phenotypes were flagged as having an association with idiopathic pulmonary fibrosis (IPF).

July 23rd 2025

Single-Dose Fosfomycin Found as Safe, Effective as Other Antibiotics for Uncomplicated UTIs

Brooke McCormick

Fosfomycin proved to be a safe, effective alternative for treating uncomplicated urinary tract infections (UTIs), potentially reducing antibiotic resistance and costs.

Related Content

Advertisement

July 25th 2025

Genetic Study Finds Hypothyroidism May Increase PAH Risk

Maggie L. Shaw

A nascent hypothesis regarding pulmonary arterial hypertension (PAH) is that there is a link between thyroid dysfunction and PAH risk; much remains to be investigated to prove causality.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 24th 2025

High Burdens of Drug Resistance Found in Children With HIV

Julia Bonavitacola

Mother-to-child transmission often led to pretreatment drug resistance and acquired drug resistance in children living with HIV.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 23rd 2025

Immune Cell Phenotypes Linked With Hypothyroidism, IPF

Jared Kaltwasser

Thirty-six immune cell phenotypes were flagged as having an association with idiopathic pulmonary fibrosis (IPF).

July 23rd 2025

Single-Dose Fosfomycin Found as Safe, Effective as Other Antibiotics for Uncomplicated UTIs

Brooke McCormick

Fosfomycin proved to be a safe, effective alternative for treating uncomplicated urinary tract infections (UTIs), potentially reducing antibiotic resistance and costs.